EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Trends in oncology drug lags in Japan from 2001 to 2020: A cross‐sectional study

Hideki Maeda iD, Asuka Hara, Momoka Ofuchi, Riko Shingai, Toshihiro Misumi iD, Yuna Murai

Clinical and Translational Science · 2023

DOI: 10.1111/cts.13660 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, 2023. Verfasst von Hideki Maeda und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Regulatory Science, Faculty of Pharmacy, Meiji Pharmaceutical University, Kiyose, Japan. Hauptthemen laut MEDLINE: Drug Approval, Antineoplastic Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: JSPS KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anticancer drugs are essential in the treatment of serious diseases, but their applications are limited by drug lags. This study investigated the characteristics of anticancer drugs approved in Japan over the past 20 years and compared the drug lag trends between Japan and the US. We assessed the changes in drug lag between Japan and the US and the factors affecting the drug lags using publicly available data for anticancer drugs approved in Japan from January 2001 to December 2020. A total of 299 anticancer drugs were approved in Japan in the last 20 years. The approval lag median between the US and Japan was 498 days (16.6 months), peaking in 2002, and decreasing annually thereafter. The minimum approval lag was 173.5 days (5.7 months) in 2018. Multivariate regression analysis revealed that “global simultaneous strategy,” “catch‐up strategy,” and “immunotherapy” are major factors shortening the drug lag. In the past decade, 226 anticancer drugs were approved in Japan. The drug lag for anticancer drugs between Japan and the US peaked in 2002, after which it declined sharply to less than a year. However, the lag was shortest in 2018.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalAntineoplastic AgentsHumansCross-Sectional StudiesJapanTime Factors

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Regulatory Science, Faculty of Pharmacy, Meiji Pharmaceutical University, Kiyose, Japan.
  • Department of Data Science, National Cancer Center Hospital East, Kashiwa, Japan.

ORCID-Profile: Hideki Maeda, Toshihiro Misumi

Förderung

  • JSPS KAKENHI

Zitieren

APA

Maeda, H., Hara, A., Ofuchi, M., Shingai, R., Misumi, T., & Murai, Y. (2023). Trends in oncology drug lags in Japan from 2001 to 2020: A cross‐sectional study. Clinical and Translational Science. https://doi.org/10.1111/cts.13660

Vancouver

Maeda H, Hara A, Ofuchi M, Shingai R, Misumi T, Murai Y. Trends in oncology drug lags in Japan from 2001 to 2020: A cross‐sectional study. Clinical and Translational Science. 2023. doi:10.1111/cts.13660

BibTeX
@article{Maeda2023,
  author = {Maeda, Hideki and Hara, Asuka and Ofuchi, Momoka and Shingai, Riko and Misumi, Toshihiro and Murai, Yuna},
  title = {Trends in oncology drug lags in Japan from 2001 to 2020: A cross‐sectional study},
  journal = {Clinical and Translational Science},
  year = {2023},
  doi = {10.1111/cts.13660}
}
Kostenlos starten →